Q3 2017 EPS Estimates for Myriad Genetics, Inc. Reduced by Analyst (MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) – Investment analysts at Jefferies Group decreased their Q3 2017 earnings per share (EPS) estimates for Myriad Genetics in a report issued on Wednesday. Jefferies Group analyst B. Couillard now anticipates that the brokerage will earn $0.24 per share for the quarter, down from their prior forecast of $0.28. Jefferies Group has a “Hold” rating and a $18.00 price target on the stock.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, February 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.02. The company earned $196.50 million during the quarter, compared to analyst estimates of $189.72 million. Myriad Genetics had a return on equity of 12.02% and a net margin of 8.08%. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 earnings per share.

WARNING: This piece was published by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another publication, it was stolen and reposted in violation of US & international copyright laws. The correct version of this piece can be read at http://sleekmoney.com/q3-2017-eps-estimates-for-myriad-genetics-inc-reduced-by-analyst-mygn/1655731.html.

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Several other research analysts have also recently weighed in on the stock. Stephens cut shares of Myriad Genetics from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, November 2nd. Deutsche Bank AG restated a “sell” rating and issued a $15.00 price objective on shares of Myriad Genetics in a research report on Wednesday, January 18th. Zacks Investment Research upgraded shares of Myriad Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 1st. Barclays PLC restated an “equal weight” rating and issued a $22.00 price objective on shares of Myriad Genetics in a research report on Tuesday, December 27th. Finally, TheStreet cut shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 1st. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $27.64.

Shares of Myriad Genetics (NASDAQ:MYGN) opened at 15.99 on Friday. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $39.74. The stock has a 50 day moving average price of $16.35 and a 200-day moving average price of $19.53. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of 18.07 and a beta of 0.26.

A number of institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio raised its position in shares of Myriad Genetics by 0.3% in the second quarter. Public Employees Retirement System of Ohio now owns 150,895 shares of the company’s stock worth $4,617,000 after buying an additional 443 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of Myriad Genetics by 6.3% in the second quarter. Sterling Capital Management LLC now owns 1,523,758 shares of the company’s stock worth $46,627,000 after buying an additional 90,420 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Myriad Genetics by 12.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 546,578 shares of the company’s stock worth $16,726,000 after buying an additional 60,723 shares during the last quarter. Numeric Investors LLC raised its position in shares of Myriad Genetics by 586.6% in the second quarter. Numeric Investors LLC now owns 409,200 shares of the company’s stock worth $12,522,000 after buying an additional 349,600 shares during the last quarter. Finally, BlackRock Advisors LLC raised its position in shares of Myriad Genetics by 1.4% in the second quarter. BlackRock Advisors LLC now owns 136,647 shares of the company’s stock worth $4,181,000 after buying an additional 1,839 shares during the last quarter.

WARNING: This piece was published by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another publication, it was stolen and reposted in violation of US & international copyright laws. The correct version of this piece can be read at http://sleekmoney.com/q3-2017-eps-estimates-for-myriad-genetics-inc-reduced-by-analyst-mygn/1655731.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

5 Day Chart for NASDAQ:MYGN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/q3-2017-eps-estimates-for-myriad-genetics-inc-reduced-by-analyst-mygn/1655731.html

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *